| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2511557 | Antiviral Research | 2006 | 6 Pages |
Abstract
The discovery that some nucleoside analogues endowed with the unnatural l-configuration can possess biological activities has been a significant breakthrough in antiviral chemotherapy. In this regard, lamivudine (3TC) was the first l-nucleoside enantiomer approved against HIV and HBV, and several other l-nucleosides are currently under clinical development as antiviral agents
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Virology
Authors
Christophe Mathé, Gilles Gosselin,